| Contributors: |
Pini, L.; Bagnasco, D.; Beghe, B.; Braido, F.; Cameli, P.; Caminati, M.; Caruso, C.; Crimi, C.; Guarnieri, G.; Latorre, M.; Menzella, F.; Micheletto, C.; Vianello, A.; Visca, D.; Bondi, B.; El Masri, Y.; Giordani, J.; Mastrototaro, A.; Maule, M.; Pini, A.; Piras, S.; Zappa, M.; Senna, G.; Spanevello, A.; Paggiaro, P.; Blasi, F.; Canonica, G. W. |
| Description: |
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Partial and complete clinical remission (CR) were assessed. Data were analyzed with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: At 36 months, benralizumab reduced the exacerbation rate by 89% and increased the forced expiratory volume in 1 second (FEV1) (+440 mL at 36 months, p < 0.0001). Benralizumab improved asthma control as well as sinonasal symptoms in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Up to 93.33% of patients either reduced or discontinued OCS; benralizumab also decreased ICS use and other asthma medications. Overall, 84.31% of patients achieved partial or complete CR. Conclusions: Benralizumab improved asthma and sinonasal outcomes up to 36 months. These findings support the potential of benralizumab to induce CR, emphasizing its role as a disease-modifying anti-asthmatic drug for the management of SEA. Further research is warranted to expand these findings by minimizing data loss and assessing benralizumab’s long-term safety. |